AST-120 Improves Cardiac Dysfunction in Acute Kidney Injury Mice via Suppression of Apoptosis and Proinflammatory NF-κB/ICAM-1 Signaling.
Wen-Ching Shen, Yu-Hsiang Chou, Li-Shian Shi...
https://pubmed.ncbi.nlm.nih.gov/33658826/Actively Recruiting
Led by Chang Gung Memorial Hospital · Updated on 2025-09-19
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the use of AST-120 Kremezin4 combined with standard care to reduce protein-bound uremic toxins, specifically indoxyl sulfate IS and p-cresyl sulfate p-CS, in patients with acute kidney disease AKD. The study aims to determine if AST-120 can help prevent worsening kidney function and slow the progression from AKD to chronic kidney disease CKD. Additionally, the trial will explore whether lowering these toxins may reduce the risk of CKD-related complications such as cardiovascular disease. The study will include 100 patients randomized into two groups one receiving AST-120 at 6 grams per day divided into three doses along with standard post-AKD care, and the other receiving only standard care. The treatment phase lasts 14 days, followed by blood tests and clinical assessments at baseline, day 14, day 90, and day 180. These tests will measure toxin levels, kidney function, and urine markers. Monitoring for major adverse kidney and cardiovascular events will also occur during follow-up visits. Participants will provide blood samples at four key timepoints to assess indoxyl sulfate, p-cresyl sulfate, serum creatinine, estimated glomerular filtration rate eGFR, and urine albumin-to-creatinine ratio UACR. Demographic and clinical data will be collected at the start. The trial includes regular health assessments and adverse event monitoring throughout. The primary measure is the change in serum indoxyl sulfate levels, with additional kidney function and toxin markers tracked over six months.
CONDITIONS
AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
C
Chih-Hsiang Chang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chang Gung Memorial Hospital
Lead Sponsor
Conmed Pharmaceutical & Bio-Medical Corporation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 days
Participants receive either AST-120 (6 g/day divided into three doses) along with standard post-AKD care or standard post-AKD care alone for acute kidney disease.
1 baseline visit and 1 visit at Day 14 (in-person)
Duration - Approximately 5 months
Participants are monitored for kidney function and adverse events after treatment ends, including assessment of major adverse kidney and cardiovascular events.
2 visits at Day 90 and Day 180 (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Wen-Ching Shen, Yu-Hsiang Chou, Li-Shian Shi...
https://pubmed.ncbi.nlm.nih.gov/33658826/Daisuke Nagata, Hiromichi Yoshizawa
https://pubmed.ncbi.nlm.nih.gov/33311993/Pauline Caillard, Youssef Bennis, Isabelle Six...
https://pubmed.ncbi.nlm.nih.gov/35622583/Suguru Yamamoto, Junichiro J Kazama, Kentaro Omori...
https://pubmed.ncbi.nlm.nih.gov/26395517/Yong Jin Lim, Nicole A Sidor, Nicholas C Tonial...
https://pubmed.ncbi.nlm.nih.gov/33668632/Chiao-Yin Sun, Shih-Chung Chang, Mai-Szu Wu
https://pubmed.ncbi.nlm.nih.gov/22237753/Fellype C Barreto, Daniela V Barreto, Sophie Liabeuf...
https://pubmed.ncbi.nlm.nih.gov/19696217/Gerald Schulman, Tomas Berl, Gerald J Beck...
https://pubmed.ncbi.nlm.nih.gov/25349205/Chiao-Yin Sun, Hsiang-Hao Hsu, Mai-Szu Wu
https://pubmed.ncbi.nlm.nih.gov/22610984/Maxime Espi, Laetitia Koppe, Denis Fouque...
https://pubmed.ncbi.nlm.nih.gov/32384617/Chang Gung Memorial Hospital
Lead Sponsor
Conmed Pharmaceutical & Bio-Medical Corporation
Collaborating Sponsor